Company · MGX
Metagenomi Therapeutics, Inc.
Nasdaq's symbol directory lists MGX on Nasdaq as “Metagenomi Therapeutics, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders bought on 1 occasion ($23K); insiders sold on 3 occasions ($5K); 1 filing by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Reid Laurence bought $23K
- Irish Jian, President and Chief Executive Officer sold $2K
- Wapnick Pamela, Chief Financial Officer sold $2K
- Wein Matthew, General Counsel, Compliance Officer and Corporate Secretary sold $415
Every trade (4)
- BUYReid Laurence bought $23K
- SELLIrish Jian, President and Chief Executive Officer sold $2K
- SELLWapnick Pamela, Chief Financial Officer sold $2K
- SELLWein Matthew, General Counsel, Compliance Officer and Corporate Secretary sold $415
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- Thomas Brian C. 7.3%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Regulation FD disclosure Sep 22, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.